You're acting suprised that a small cap pharma stock is setting...

You're acting suprised that a small cap pharma stock is setting ambitious and in a lot of cases unrealistic milestones. Have you seriously never come across this before. You need to take everything they say with a grain of salt and do your own due diligence to make an unbiased and informed decision. Just like a comment from the company that xanamem could be on the market as early as 2027 with success in the Phase 2b and accelerated approval. This would be great. But is it realistic? You need to make your own mind up about things like this instead of just getting your knickers in a knot when it doesn't pan out.

For the xanamia trial the rate of enrolment was always going to be a potential issue by using the ptau181 biomarker because approximately 50% of participants that are screened for the trial on the expectation that they have mild alzheimer's won't actually pass this test because they've been misdiagnosed. So if we have the same number of trial sites as Xanadu and we're only recruiting 50% of the participants that enrol for the trial then it doesn't take a genius to work out that recruitment is going to be slower. We'll get a better idea when the quarterly report comes out how things are going. But the company was always going to push out the timelines. It was just a matter of when they came clean to the market. I wouldn't be suprised to see them add more sites prior to mid-2025 to ensure we get full enrolment by the end of the year. That's what's more important in order to hold the final readout date. It doesn't matter if timing for the interim results pushes back if they can ramp up recruitment to make sure the trial finished in H2 2026.

And to be clear I never said the MDD results were fantastic. I personally don't think this will attract a partner yet until they've shown statistical and clinical significance with MADRS as the primary endpoint in a second Phase 2b trial. My point was that an anti-depression drug is more valuable and will have a larger TAM if it actually treats depression and not just improves cognition.